Sunshine Lake Pharma Co., Ltd. Stock Price

SEHK:6887 Community·HK$25.3b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Create a narrative

6887 Share Price Performance

HK$43.86

10.55 (31.69%)

HK$43.86

10.55 (31.69%)

HK$43.86

Sat, 4 Apr 26

Share Pricen/a

6887 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Trending Discussion

Snowflake Analysis

Excellent balance sheet with low risk.

3 Risks

0 Rewards

View Full Analysis

Sunshine Lake Pharma Co., Ltd. Key Details

Last Reported Earnings

Dec 31, 2024

Next Reporting Earnings

n/a

: 0.84
: 75.03%
: 12.96%
: 22.6%

View Full Analysis

About 6887

Founded: 2001
Employees: 4861
CEO: Wenjia Li
WebsiteView website: www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products for the treatment of infectious diseases, chronic diseases, and oncology. It offers Kewei for the treatment of influenza; Dongweien for the treatment of hepatitis C; and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin, and Moxifloxacin Hydrochlorid, as well as active pharmaceutical ingredients. The company also engages in the wholesale, retail, import, and export of drugs. The company was formerly known as Sunshine Lake Pharma Ltd. The company was incorporated in 2001 and is based in Dongguan, China.